Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
CMS BALANCE Model Targets Rural Access Gaps for GLP-1 Weight Loss Drugs
New federal initiative pairs Medicare and Medicaid GLP-1 coverage with rural health investments, but voluntary participation raises questions about equitable access.
The DoseFDA Approves Higher-Dose Wegovy Under New Fast-Track Review Program
The FDA approved Wegovy HD (7.2 mg) under its new National Priority Voucher program, delivering 20.7% average weight loss and cutting review times to just 2 months.
The DoseThe Best Online GLP-1 Providers in 2026: An In-Depth Comparison of 10 Platforms
We evaluated 10 telehealth GLP-1 platforms across pricing, medications, insurance, clinical quality, and patient experience. Here are the results — from the $99/month budget option to the specialist-led programs.
The DoseStopping GLP-1 Drugs Rapidly Erases Heart Benefits, Major Study Finds
Large study of 333,000+ patients shows stopping GLP-1 medications can increase cardiovascular risk by 22% within two years, largely erasing years of heart protection benefits.
The DoseMajor Insurers Adding GLP-1 Coverage as Employer Demand Surges in 2026
UnitedHealthcare, Cigna, and Aetna have expanded GLP-1 weight management coverage for employer-sponsored plans in 2026, driven by corporate demand and emerging data on healthcare cost savings.
The DoseThree States Expand Telehealth Prescribing Rules for Weight Loss Medications
California, Texas, and Florida have enacted new regulations that make it easier for clinicians to prescribe GLP-1 medications through telehealth platforms, removing prior in-person visit requirements.
The DoseSELECT Trial Follow-Up Confirms Lasting Cardiovascular Benefits of Semaglutide
A two-year follow-up analysis of the landmark SELECT trial shows semaglutide's cardiovascular protection persists and may strengthen over time, with a 23% reduction in major cardiac events.
The DoseNovo Nordisk Breaks Ground on $4.1 Billion Manufacturing Facility in North Carolina
Novo Nordisk has begun construction on a $4.1 billion fill-finish manufacturing campus in Johnston County, North Carolina, expected to create 2,000 jobs and triple U.S. production capacity.
The DoseFDA Sends Warning Letters to 21 Compounding Pharmacies Over Semaglutide Quality
The FDA has issued warning letters to 21 compounding pharmacies citing quality failures in their semaglutide products, including incorrect potency and sterility violations.
The DoseRetatrutide Phase 3 Trial Results Show 24% Average Body Weight Reduction
Eli Lilly's triple-hormone receptor agonist retatrutide achieved 24.2% weight loss in a pivotal Phase 3 trial, the largest reduction seen in any obesity drug study to date.
The DoseMedicare GLP-1 Coverage Bill Gains Bipartisan Support in Senate
A bipartisan Senate bill that would require Medicare Part D to cover GLP-1 medications for weight management has secured 14 co-sponsors, bringing it closer to a floor vote.
The DoseEli Lilly Ramps Up Zepbound Manufacturing as Supply Shortages Expected to Ease
Eli Lilly says its $9 billion manufacturing expansion is bearing fruit, with most Zepbound doses now consistently available at pharmacies for the first time since launch.